Ursodeoxycholic Acid Market Revenue Analysis
By Leading Players Biotavia Labs, Daewoong
Chemical
Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones
and to treat and prevent the progression of cystic fibrosis-related liver disorder. UDCA modifies
the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of
nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and
progression to cirrhosis. Moreover it can improve long-term survival in patients with primary
biliary cirrhosis.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2199
Significant improvement in liver health can be achieved during UDCA therapy in patients with
intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver
disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis,
graft related liver disease, and in some pediatric cholestatic liver diseases.
The global ursodeoxycholic acid market size was valued at US$ 346.2 million in 2017, and is
expected to witness a CAGR of 7.0% over the forecast period (2018 – 2026).
Market Dynamics
Increasing incidence of gallstones and cystic fibrosis is expected to propel demand for UDCA,
thereby driving the ursodeoxycholic acid market growth. According to a study published in the
journal Gastroenterology, 2009, cholelithiasis, the presence of gallstones in the gallbladder, is
estimated to occur in 10 – 15% of the adult population in the U.S. Although, gallstones can
occur at any age, it is rare before the age of 30. A progressive increase in risk of cholelithiasis
is observed with age and in patients over 50, the prevalence ranges is between 25-30%.
Report includes chapters which deeply display the following deliverable about industry :
• Ursodeoxycholic Acid Market Research Objective and Assumption
• Ursodeoxycholic Acid Market Purview - Report Description, Executive Summary, and Coherent